News
ITCI
--
0.00%
--
New Ventures Funds Rebrands as Scientia Ventures
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com. This reflects the broadening of the firm's strategic direction since launching its 3rd fund in 2017 to reflect its focus on transformational
PR Newswire · 10/02 11:00
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Dr. Suresh Durgam to the position of Chief
GlobeNewswire · 10/01 21:30
Intra-Cellular Therapies: Navigating Choppy CNS Treatment Waters With Aplomb
Intra-Cellular won approval for Schizophrenia treatment Caplyta in Dec 2019 after a protracted review by the FDA. The marketing push began in Q1 but has been disrupted by COVID-19.The company looks set to follow up with a bipolar I and II approval based on positive data from 2 out of 3 phase 3 trials.These are huge markets and blockbuster sales may not be out of the question.With its science validated, Intra-Cellular also has a promising pipeline in development.There is a case to argue that the company is under-hyped and its shares could be worth as much as $60 based on DCF analysis. It would make an attractive acquisition target, in my view.
Seekingalpha · 09/30 22:36
PLM, REAL, SPI and BEAM among after-hours movers
Gainers: [[RLGT]] +11.3%. [[PLM]] +10.1%. [[DPW]] +6.7%. [[AFMD]] +6.6%. [[REAL]] +6.4%.Losers: [[AMBO]] -16.6%. [[SPI]] -6.8%. [[BEAM]] -5.5%. [[JAMF]] -4.5%. [[ITCI]] -4.3%.
Seekingalpha · 09/28 21:46
Insider Weekends: Tamara Gustavson Puts $8 Million Into Public Storage
Insider buying increased significantly last week.Notable Insider Buys: Public Storage, IGM Biosciences, Inc., Cassava Sciences, Inc., Intra-Cellular Therapies, Inc., Nikola Corporation.Notable Insider Sells: Scientific Games Corporation, Guardant Health, Inc., Antero Midstream Corporation, The Boston Beer Company, Inc., Zscaler, Inc.
Seekingalpha · 09/21 11:12
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
The following slide deck was published by Intra-Cellular Therapies, Inc. in conjunction with this event.
Seekingalpha · 09/17 23:20
Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman
GlobeNewswire · 09/15 12:00
Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman
GlobeNewswire · 09/14 13:00
What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)?
A look at the shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) can tell us which group is most powerful...
Simply Wall St. · 09/11 13:42
ITCI, AMRS among premarket losers
Evofem Biosciences (EVFM) -14%.Amyris (AMRS) -11% after Lavvan files $881M lawsuit.Muscle Maker (GRIL) -11%.Brigham Minerals (MNRL) -10% after pricing secondary offering.Satsuma Pharmaceuticals (STSA) -7% on yesterday's news of late-stage STS101 study and analysts downgrade.Spero Therapeutics (SPRO) -8% after pricing equity
Seekingalpha · 09/11 12:21
Stick With the Intra-Cellular Rally for Another 25% Upside, Says Analyst
TipRanks · 09/10 17:38
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends
GlobeNewswire · 09/09 21:01
Intra-Cellular commences $350M equity offering
Intra-Cellular Therapies (ITCI) launches a $350M public offering of common stock. Price, volume and terms have yet to be announced.Shares down 3% after hours.
Seekingalpha · 09/09 20:11
Mid-Afternoon Market Update: Nasdaq Surges 300 Points; Slack Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 2.32% to 28140.09 while the NASDAQ rose 2.87% to 11,159.42. The S&P also rose, gaining 2.44% to 3,413.24.
Benzinga · 09/09 18:30
Positive Test Results For Bipolar Treatment Sends Intra-Cellular Stock Soaring
Investor's Business Daily · 09/09 17:19
Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to 3,404.35.
Benzinga · 09/09 16:04
Intra-Cellular Therapies, Trillium Therapeutics leads gainers, Co-Diagnostics, Applied Genetic Technologies among losers
Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.
Seekingalpha · 09/09 15:07
Mid-Morning Market Update: Markets Open Higher; AstraZeneca Halts Coronavirus Vaccine Study
Following the market opening Wednesday, the Dow traded up 1.65% to 27955.71 while the NASDAQ rose 1.92% to 11055.64. The S&P also rose, gaining 1.81% to 3,392.02.
Benzinga · 09/09 14:24
ROCE Insights For Intra-Cellular Therapies
During Q2, Intra-Cellular Therapies's (NASDAQ: ITCI) reported sales totaled $1.91 million. Despite a 32.16% in earnings, the company posted a loss of $64.87 million. Intra-Cellular Therapies collected $1.08 million in revenue during Q1, but reported earnings showed a $49.09 million loss.What Is ROCE
Benzinga · 09/09 14:08
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about INTRA CELLULAR through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
More